| Charles Malcolm Hines, MD | |
|
90 Southside Ave, Suite 350, Asheville, NC 28801-4160 | |
| (828) 277-4810 | |
| Not Available |
| Full Name | Charles Malcolm Hines |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 90 Southside Ave, Asheville, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881681617 | NPI | - | NPPES |
| 19262 | Other | MA | HEALTH NEW ENGLAND |
| 3112624 | Medicaid | MA | |
| 395316 | Medicaid | SC | |
| 1881681617 | Medicaid | NC | |
| J17404 | Other | MA | BLUE CROSS |
| Entity Name | Inpatient Consultants Of North Carolina Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669422846 PECOS PAC ID: 5991720591 Enrollment ID: O20051012001172 |
News Archive
Following a highly competitive evaluation process, National Patient Services (NPS) - A Triplefin Company has been awarded two multi-year contracts to provide Alternative Sampling and Marketing programs for two Fortune 50 Pharmaceutical Manufacturing companies.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
A study by Nanyang Technological University, Singapore has found that as the type of COVID-19 misinformation rectified by Singapore's mainstream news media evolved over the course of the pandemic, the role played by the media in debunking those myths became increasingly important to citizens in the nation's fight to manage the outbreak.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Affymax, Inc. today announced the completion of the sale at par value of all auction rate securities held by UBS AG and its affiliates in a transaction which generated net proceeds of $5.0 million to Affymax, after payment of $5.4 million from the proceeds to retire a loan due to UBS. From April 1, 2010 through June 30, 2010, $3.7 million of the UBS ARS were settled at par value resulting in a corresponding reduction in the balance of UBS ARS and related loan since the first quarter 2010. The company now has no debt liability on its balance sheet.
› Verified 3 days ago
| Entity Name | Nm Pacs 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366928749 PECOS PAC ID: 3375892060 Enrollment ID: O20200109003016 |
News Archive
Following a highly competitive evaluation process, National Patient Services (NPS) - A Triplefin Company has been awarded two multi-year contracts to provide Alternative Sampling and Marketing programs for two Fortune 50 Pharmaceutical Manufacturing companies.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
A study by Nanyang Technological University, Singapore has found that as the type of COVID-19 misinformation rectified by Singapore's mainstream news media evolved over the course of the pandemic, the role played by the media in debunking those myths became increasingly important to citizens in the nation's fight to manage the outbreak.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Affymax, Inc. today announced the completion of the sale at par value of all auction rate securities held by UBS AG and its affiliates in a transaction which generated net proceeds of $5.0 million to Affymax, after payment of $5.4 million from the proceeds to retire a loan due to UBS. From April 1, 2010 through June 30, 2010, $3.7 million of the UBS ARS were settled at par value resulting in a corresponding reduction in the balance of UBS ARS and related loan since the first quarter 2010. The company now has no debt liability on its balance sheet.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Malcolm Hines, MD 90 Southside Ave, Suite 350, Asheville, NC 28801-4160 Ph: () - | Charles Malcolm Hines, MD 90 Southside Ave, Suite 350, Asheville, NC 28801-4160 Ph: (828) 277-4810 |
News Archive
Following a highly competitive evaluation process, National Patient Services (NPS) - A Triplefin Company has been awarded two multi-year contracts to provide Alternative Sampling and Marketing programs for two Fortune 50 Pharmaceutical Manufacturing companies.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
A study by Nanyang Technological University, Singapore has found that as the type of COVID-19 misinformation rectified by Singapore's mainstream news media evolved over the course of the pandemic, the role played by the media in debunking those myths became increasingly important to citizens in the nation's fight to manage the outbreak.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Affymax, Inc. today announced the completion of the sale at par value of all auction rate securities held by UBS AG and its affiliates in a transaction which generated net proceeds of $5.0 million to Affymax, after payment of $5.4 million from the proceeds to retire a loan due to UBS. From April 1, 2010 through June 30, 2010, $3.7 million of the UBS ARS were settled at par value resulting in a corresponding reduction in the balance of UBS ARS and related loan since the first quarter 2010. The company now has no debt liability on its balance sheet.
› Verified 3 days ago
Dr. William R Harlan Iii, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 191 Biltmore Ave, Asheville, NC 28801 Phone: 828-254-0881 Fax: 828-254-1614 | |
Dr. Nellie E. L. Fleming, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville Hospitalist Group, Asheville, NC 28801 Phone: 828-213-4411 Fax: 828-285-9740 | |
Dr. Wade H Saunders Iii, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-274-6000 Fax: 828-277-6350 | |
Marianne Soufas, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 68 Sweeten Creek Rd, Asheville, NC 28803 Phone: 828-274-9567 Fax: 828-255-2865 | |
Dr. Bryan J Pace, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-274-6000 Fax: 828-274-6025 | |
Zachary Dillon Glenn, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Dr. Jeffrey Tyler Ramsey, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 123 Hendersonville Rd, Asheville, NC 28803 Phone: 828-407-2415 Fax: 828-412-4171 |